Navigation Links
Reducing Risk and Ensuring Effectiveness in Competitive Intelligence Groups
Date:2/23/2011

CHAPEL HILL, N.C., Feb. 23, 2011 /PRNewswire/ -- Competitive Intelligence (CI) groups play a vital role in helping biopharmaceutical organizations navigate today's volatile business environment. It is CI groups' marketplace insights from primary and secondary research that set an organization's strategic and tactical direction for commercial success. But in the closely regulated pharmaceutical industry, organizations need to have policies and guidelines in place for conducting CI that reduce corporate risk -- but don't inhibit gathering of critical information.

To help companies maintain effective CI groups and safely operate in the current regulatory environment, Best Practices, LLC has published a new report: "Best Practices in Competitive Intelligence: Policies & Guidelines that Reduce Corporate Risks."

This report will help organizations understand:

  • How organizations can optimize their CI operations while working within defined guidelines.
  • How CI organizations work with Legal to develop policies and guidelines.
  • Practices for collection, use and sources of primary data -- including employment of third party vendors for primary data collection.
  • CI resources, staffing and structure.

The study found that marketing, business analytics and medical affairs functions are the leading internal contributors of CI. However, those sources for primary CI are neither as frequently used nor as highly valued as the top external sources, which are medical congresses, vendors and KOLs.

Twenty-seven leaders of Competitive Intelligence and related functions at 22 leading pharmaceutical companies participated in the research project. Field interviews and study analysis produced many observations and benchmarks for organization growth and profitability from effective CI operations. CI leaders can use this research to help create or maintain policies and guidelines regarding CI operations as well as to compare their data collection practices and resource/structural benchmarks with those of leading organizations.

To learn more about this report, download a complimentary report excerpt at http://www3.best-in-class.com/rr1043.htm. For related research, visit our Best Practices, LLC Web site at www.best-in-class.com/.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For more than 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more information about the company, go to www.best-in-class.com.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PROTECT II Interim Results Demonstrate That Impella Is Not Superior to the Intra-Aortic Balloon Pump in Reducing Major Adverse Events in High Risk Patients Receiving Percutaneous Coronary Interventions
2. DSM Receives European Outsourcing Awards for Carbon Footprint Reducing Technology
3. Daily Intake of Yakult Is Efficacious in Reducing Incidence of Acute Diarrhea in Young Children
4. Medications Effective in Reducing Risk of Breast Cancer But Increase Risk of Adverse Effects, New Report Says
5. Iontophoretic Drug Delivery System (IDDS) Containing Lidocaine and Epinephrine is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in a Phase 2 Clinical Trial
6. Adult Circumcision Reduces Risk of HIV Transmission Without Reducing Sexual Pleasure
7. Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production
8. Consensus Document Outlines Practical Steps for Reducing Gastrointestinal Risks of Antiplatelet and NSAID Use
9. Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
10. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
11. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... MINNEAPOLIS , April 20, 2017  Cogentix ... company focused on providing the Urology, Uro/Gyn and ... reported that Ash Keswani has joined the Company ... In this newly created position, Mr. Keswani will ... and CEO. "Our organization is delighted ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
(Date:4/20/2017)... 20, 2017 Eyevensys, a private ... non-viral gene expression technology that enables the safe, local, ... address a wide range of ophthalmic diseases, announces it ... products Regulatory Agency (MHRA) to advance its technology into ... ...
Breaking Medicine Technology:
(Date:4/29/2017)... (PRWEB) , ... April 29, 2017 , ... ... celebrate the profession and recognize the positive impact veterinarians have on animal health ... and the World Organization for Animal Health (OIE) choose a theme each year ...
(Date:4/28/2017)... NC (PRWEB) , ... April 28, 2017 , ... ... announce its new partnership with the Home Care Association of America (HCAOA). This ... and Private Duty Accreditation services, as well as discounts on Accreditation University (AU) ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Beginning in ... of their formulas. This begins with the popular ClearLungs Extra Strength formula. To ensure ... changing the formula in the following ways:, , Removal of ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark is ... with diabetes. The GlycoMark test provides a clinically proven one- to two-week measure ...
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
Breaking Medicine News(10 mins):